Guest guest Posted January 28, 2009 Report Share Posted January 28, 2009 Debiopharm Group Announces Clinical Update on Debio 025 in Hepatitis C From the PharmaLive.com News Archive (January 26, 2009)LAUSANNE, Switzerland, January 26, 2009 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Read Full Article Article Summary Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2009 Report Share Posted January 28, 2009 Debiopharm Group Announces Clinical Update on Debio 025 in Hepatitis C From the PharmaLive.com News Archive (January 26, 2009)LAUSANNE, Switzerland, January 26, 2009 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Read Full Article Article Summary Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2009 Report Share Posted January 28, 2009 Debiopharm Group Announces Clinical Update on Debio 025 in Hepatitis C From the PharmaLive.com News Archive (January 26, 2009)LAUSANNE, Switzerland, January 26, 2009 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Read Full Article Article Summary Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2009 Report Share Posted January 28, 2009 Debiopharm Group Announces Clinical Update on Debio 025 in Hepatitis C From the PharmaLive.com News Archive (January 26, 2009)LAUSANNE, Switzerland, January 26, 2009 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Read Full Article Article Summary Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.